U.S. Markets close in 35 mins

CryoPort Inc (CYRX) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

CryoPort Inc (CYRX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. CryoPort Inc provides cryogenic logistics solutions to the life sciences industry through its proprietary packaging, information technology, and cold chain logistics expertise. It offers logistics solutions for stem cells and CAR-T cells. CryoPort Inc has a market cap of $350.780 million; its shares were traded at around $11.60 with and P/S ratio of 18.41. CryoPort Inc had annual average EBITDA growth of 31.80% over the past five years.


For the last quarter CryoPort Inc reported a revenue of $5.69 million, compared with the revenue of $3.32 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $19.6 million, an increase of 64.2% from last year. For the last five years CryoPort Inc had an average revenue growth rate of 73.6% a year.

The reported loss per diluted share was 34 cents for the year, compared with the loss per share of $4.486 in the previous year. The CryoPort Inc had an operating margin of -44.05%, compared with the operating margin of -66.03% a year before. The 10-year historical median operating margin of CryoPort Inc is -875.12%. The profitability rank of the company is 5 (out of 10).

At the end of the fiscal year, CryoPort Inc has the cash and cash equivalents of $37.3 million, compared with $15.0 million in the previous year. The long term debt was $14.7 million. CryoPort Inc has a financial strength rank of 9 (out of 10).

At the current stock price of $11.60, CryoPort Inc is traded at 13.6% premium to its historical median P/S valuation band of $10.21. The P/S ratio of the stock is 18.41, while the historical median P/S ratio is 16.20. The stock gained 17.50% during the past 12 months.

For the complete 20-year historical financial data of CYRX, click here.

This article first appeared on GuruFocus.